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ABSTRACT
Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great
promise for the treatment of autoimmune diseases and for the prevention of destructive
immune responses after transplantation. The methodologies for generating tolAPC
vary greatly between different laboratories, making it difficult to compare data from
different studies; thus constituting a major hurdle for the development of standardised
tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC
field to generate a minimum information model for tolAPC (MITAP), providing
a reporting framework that will make differences and similarities between tolAPC
products transparent. In this way,MITAP constitutes a first but important step towards
the production of standardised and reproducible tolAPC for clinical application.
Subjects Clinical Trials, Immunology, Translational Medicine, Computational Science
Keywords Cell therapy, Minimum information model, Antigen-presenting cells, Autoimmune
disease, Transplantation, Tolerogenic dendritic cells, Regulatory macrophages, Reporting
guidelines
INTRODUCTION
Immunotherapy with whole living cells shows great promise for the treatment of a
wide variety of complex diseases. A recent innovation in this field is the use of myeloid
antigen-presenting cells (APC) with immunoregulatory function to treat autoimmune
diseases, or to prevent destructive immune reactions after organ—or haematopoietic
stem cell-transplantation (Amodio & Gregori, 2012; Hutchinson, Riquelme & Geissler, 2012;
Hilkens & Isaacs, 2013; Van Brussel et al., 2014; Creusot et al., 2014; Thomas, 2014; Morelli
& Thomson, 2014; Ten Brinke et al., 2015). Examples of these immunoregulatory APC
include tolerogenic dendritic cells (tolDC) and regulatory macrophages (Mreg). The main
advantage of these tolerogenic/regulatory APC (hereafter referred to as tolAPC) therapies
over conventional immunosuppressive drugs is that these cells are uniquely equipped
to specifically target harmful T-cell responses to auto- or allo-antigens. Thus, tolAPC
act in an antigen-specific manner and do not cause general immunosuppression after
exposure to antigen or in the allogeneic transplant setting—they are, therefore, less likely
to affect protective immune responses to invading pathogens. More remarkably, as tolAPC
induce or restore immune tolerance, and immune tolerance is a self-reinforcing state, the
beneficial effects of tolAPC treatment are expected to continue beyond the lifespan of
these therapeutic cells. Thus, tolAPC therapy holds the promise of a potentially curative
treatment with low toxicity.
A variety of therapeutic tolAPC products have been developed over the last decade, and
a number of these have recently been tested, or are undergoing testing in the clinic. Phase
I trials with autologous tolAPC have been completed for type I diabetes (Giannoukakis et
al., 2011), rheumatoid arthritis (Benham et al., 2015; Bell et al., 2016) and Crohn’s disease
(Jauregui-Amezaga et al., 2015), and further phase I trials for multiple sclerosis, allergic
asthma and kidney transplantation are in progress (Ten Brinke et al., 2015). So far the
results are highly encouraging from a safety standpoint, and further phase II clinical trials
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to test the efficacy of tolAPC therapies are under development, with the first tolDC phase
II trial in type I diabetes recruiting imminently.
An outstanding and important issue within the tolAPC field is the variation in the
methods used for cell isolation and culture. Current protocols to produce tolDC or
Mreg involve the isolation of peripheral blood CD14+ monocytes followed by cell
culture under specific conditions to generate the desired type of tolAPC. For example,
monocytes can be differentiated into DC by culturing them in the presence of the
cytokines IL-4 and GM-CSF, and stable tolerogenic function can be induced in these
DC by treatment with immunosuppressive compounds (e.g., dexamethasone, IL-10) or
genetic modification to silence immunostimulatory molecules. In addition to compound
variety, the concentration used may vary, as well as the timing of administration to the
tolAPC cultures. These almost endless variations in the methodology make comparison of
different tolAPC products difficult, therefore bringing real uncertainty when comparing
safety and efficacy results from different clinical trials testing different tolAPC products in
different diseases/conditions.
MINIMUM INFORMATION MODELS (MIMS)
Minimum Information Models (MIMs) are now being recognised as an important tool
for the scientific community to use and interpret reported data, enabling comparison
between data from different studies and facilitating experimental reproducibility. While
it is simple for different laboratories to share and exchange their data, for this sharing
to be meaningful, allowing reuse and repurposing, it must share some commonality of
reporting, methodology or interpretation. This process has recently raised much interest,
for example with the 5-star open data initiative (http://5stardata.info). A MIM is the
first step in this process, providing a mechanism for the broadest level of commonality,
ensuring that different laboratories report at least the key facts about their analysis in
a clear and consistent manner, by providing a document and checklist describing the
necessary information. They are simple and easy-to-use, so are supportive rather than
burdensome for investigators. Examples of MIMs are MIAME (minimum information
about a microarray experiment) (Knudsen, Daston & Teratology, 2005) and the more
recent MIATA (minimal information about T-cell assays) (Janetzki et al., 2009; Britten et
al., 2011), the latter now actively being endorsed by seven international scientific journals.
As well as allowing sharing of data between individual laboratories, when widely used, they
also provide an excellent basis for building large integrated resources of data that can be
searched efficiently and comprehensively.
SETTING UP MITAP: COMMUNITY BUILDING AND INITIAL
ANALYSIS
Our goal was to provide a reporting framework that will make differences and similarities
of tolAPC transparent. We therefore set out to create minimum reporting guidelines for
the production process of tolAPC used in pre-clinical and/or clinical studies. We call this
MITAP (Minimum Information about Tolerogenic Antigen-Presenting cells).
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Figure 1 MITAP time line: from start to finish. 20Q: the ‘‘20 questions’’ experiment.
A critical part of building theMITAP document was community building; to enable data
sharing and commonality, the document must be broadly reflective of the opinions and
current practices ofmany laboratories within the discipline. For this, a community is needed
to provide information, feedback and tests subjects. Helpfully, we recently established a
consortium of investigators working in the field of tolerogenic cellular therapies, with the
aim of jointly addressing issues related to the translation and clinical application of these
new treatments. This consortium is called AFACTT (action to focus and accelerate cell-
based tolerance-inducing therapies—http://www.afactt.eu). It convenes every 6 months
at interactive workshops. This consortium provided an ideal vehicle for the process of
developing MITAP, which we achieved through a series of ‘‘exercises’’ that introduced
AFACTT members to the general notion of MIMs, as well as providing some initial data,
whichwe used to scope theMITAP document.We used threemain forms of exercise both of
which aimed at gathering ‘‘terms’’—basic vocabulary in usewithin the community. The first
is called the ‘‘sticky-note’’ exercise which we performed at several AFACTT meetings: for
this, each participant writes a term on a sticky-note; these are then collated and clustered on
a wall by the whole group, identifying synonyms and related terms. Secondly, we gathered
bibliographic databases from all willing AFACTT participants; abstracts were gathered
from PubMed, and analysed computationally to find words that were over-represented in
these abstracts compared to the bulk of PubMed. Finally, we built some bespoke software
to crowd-source community feedback on these terms using a simple web interface.
The conception of MITAP took place in April 2014, at the first AFACTT meeting; the
overall process of creating the MITAP document took 18 months (Fig. 1), which reflects
the nature of the process i.e., the active involvement of a diverse group of investigators and
the absolute need for incorporating feedback and suggestions from this group.
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OVERVIEW OF THE MITAP DOCUMENT
The MITAP document is divided into 4 sections that encapsulate the most important parts
of the tolAPC production process in a chronological manner. The sections describe the cells
at the start of the production process, during the differentiation/induction of tolerogenicity
process, and at the end of the production process, prior to injection into the recipient or
use in experimental assays. A final section is dedicated to aspects that are important for
understanding the application and purpose of tolAPC. The sections are described in more
detail below; for all the sections and subsections the document states clearly whether the
investigator must (required), should (if available) or may (optional) provide the relevant
information. It also advises on the use of existing taxonomies and databases to provide
the information in a uniform manner, and it suggests the use of other MIMs where
appropriate. The full MITAP document can be found on http://w3id.org/ontolink/mitap
(see also ‘Sustainability’ below).
Section 1. Cells before
This section describes the characteristics and state of the cells before they undergo any
manipulation to become a tolAPC. There are five subparts to this section. First, it asks
for essential information about the donor, including the species (surprisingly not always
mentioned in research papers), strain if working with experimental animals, and any
characteristics of the organism that are deemed to have a possible impact on the tolAPC
production process (e.g., age or sex of the organism, or whether they are takingmedication).
Second, the tissue, organ or fluid fromwhich the cells are used need to be described. Inmost
published tolAPC studies the starting material is bone marrow or peripheral blood, but it is
conceivable that for some applications investigators may want to isolate cells from specific
organs (e.g., spleen). For human studies, peripheral blood products are the most often used
source; these include freshly drawn blood by venepuncture, leukapheresis products and
buffy coats (the latter can be purchased from Bloodbanks). Third, if investigators extract
a subpopulation of cells from the initial cell source then information about the extraction
method and the equipment should be provided. Fourth, the phenotype of the extracted
cells should be described (e.g., morphology, expression of cell markers); in addition, the
proportion of the cells that display a certain characteristic needs to be reported, to provide
important information on the uniformity (‘purity’) of the cell population. In the last subpart
of this section, details on the absolute cell number and cell viability should be provided.
Section 2. Differentiation and induction of tolerogenicity
This section describes the protocol that has been used to differentiate and/or induce
tolerogenicity in the cells described in Section 1. It comprises five parts. The first part
describes the pre-culture conditions the cells are being kept in before the start of the
cell culture process to generate tolAPC. This may include freezing and thawing of
the cells. Second, the culture conditions of the cells should be provided, including
the starting cell number, cell concentration, culture medium, culture container, and
the culture environment (e.g., temperature, CO2 levels). The third part deals with the
differentiation/induction of tolerogenic function in the cells. It should be noted here that
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differentiation and induction of tolerogenicity are not necessarily interchangeable; they can
be seen as distinct processes. For example, tolAPC have been generated by differentiation of
CD14+monocytes into immature or semi-matureDC; thus, without any active induction of
pro-tolerogenic properties in the cells. In contrast, other protocols rely on the use of specific
agents to induce stable tolerogenic function in DC during differentiation from precursor
cells, and thus will use agents for both the differentiation and conferral of tolerogenicity
of/in cells. In the fourth part investigators are asked to describe the antigen (if any) they use
to load the tolAPC; this part is more likely to apply to investigators working in the field of
autoimmunity, where tolAPC need to be targeted to certain autoantigen(s), and less so to
the field of transplantation, which often (but not exclusively) uses donor-derived tolAPC
already expressing the relevant allogeneic MHC/peptide complexes. Use of autologous
APCs pulsed with donor antigen, e.g., in the form of donor cell lysate or exosomes (that
accommodates the polymorphic MHC) is also possible. The final part of this section is
about storage of the cells. If tolAPC are administered ‘freshly,’ the conditions under which
the cells are being kept in between harvesting and injection into the recipient or use in
experimental assays need to be described. On the other hand, if tolAPC are being frozen,
the process of freezing and thawing needs to be described.
Section 3. Cells after
This section describes the characteristics and state of the cells after the differentiation/in-
duction of tolerogenicity process has taken place. Two of the parts (parts 1 and 3) cover the
same type of information as in Section 1, i.e., details on the cell phenotype, number and
viability. The second part of this section provides details on any characteristics of the cells
that have been measured by means of a functional in vitro assay. This can include details
on their migratory capacity, or their ability to induce T regulatory cells.
Section 4. About the protocol
The final section of MITAP describes the general features of the protocol as a whole. The
first part provides information about any external regulatory authorities that have approved
the study, and whether the cells were produced under GLP or GMP guidelines. Second,
the purpose of the produced tolAPC should be described, e.g., prevention of transplant
rejection or restoring immune tolerance in an autoimmune disease. The relationship
between the cells and the target organism should be described i.e., allogeneic, autologous,
xenogeneic or syngeneic. Finally, the name and contact details of the corresponding author
must be provided.
The MITAP document is accompanied by a handy checklist to assist investigators in
ensuring that all the relevant detail is provided before submitting their manuscripts for
publication.
TESTING MITAP: THE “20 QUESTIONS” EXPERIMENT
The MITAP document was developed collaboratively by scientists in the AFACTT
consortium and should, therefore, be usable by this community. However, we wished
to test directly whether the document as it stood was comprehensible by individuals
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from the discipline, and that data could be entered in a consistent manner. We therefore
performed a ‘‘question-and-answer’’ experiment, a variation on the spoken parlour game
‘‘20 questions,’’ popular in the 19th and 20th centuries. We collected a list of terms—that
is short descriptive phrases that might be found in a description of a procedure to generate
tolAPC, each of which would fit into one of the categories defined by theMITAP document.
We then asked a number of scientists from the discipline, our test subjects, to place these
terms into the relevant category fromMITAP, which we call the test task. The basic premise
of the experiment is simple: if the document is clear and comprehensible, then different
test subjects should independently perform this task consistently.
The experiment was designed following a number of preconditions. First, the test task
could not be too onerous for the test subjects, so that we could maximise completion
rates; in particular, we felt that the task should take less than 30 min (including reading
documentation). Our initial trials suggested that a subject could place two phrases for
each category in MITAP in this time. Second, our terms should be representative of the
discipline, rather than a single group, as far as was possible. Therefore, we asked members
of the AFACTT group to contribute these terms, limited to two for each section in MITAP;
for the experiment, we selected a subset of these terms randomly, with minor alterations for
length. Third, our test subjects should also be representative of the discipline. Therefore,
we asked those who contributed terms to also nominate a test subject. Finally, the test
subjects were people who had not directly contributed to MITAP, nor seen the document,
nor were involved in contributing terms.
For the test itself, test subjects were presented with a set of terms and for each asked to
assess into which category it should be placed. Test subjects were given no guidance on
how to categorise terms except for the MITAP document. In fact, they were given a slightly
reduced MITAP document; the non-normative (i.e., explanatory and not a strict part of
the standard) examples were removed for the purpose of this experiment. Subjects were
also asked for some basic metadata (level of experience, discipline and so forth). The test
was conducted using an online survey system (Google forms). Strictly, this means that we
could not enforce lack of collaboration; we considered this compromise to be appropriate,
as it increased the number of test subjects and their spread across the discipline.
“20 QUESTIONS” RESULTS
The question and answer experiment was conducted over a two-week period in July
2015. We invited 24 test subjects to take part and received results from 23, representing
a 96% completion rate. Each subject categorized 44 terms from which example terms are
‘‘xenogeneic,’’ ‘‘Rattus norvegicus’’ or ‘‘immunomagnetic separation.’’
For the test task, subjects could ascribe each term to any number of MITAP categories.
A number of categories in MITAP are repetitive (cell numbers before and after the
differentiation/induction of tolerogenicity process, for example). These categories were
normalized for most of the results presented below. Answers from test subjects were
compared against our ‘‘Gold Standard’’—the answers defined by primary authors of the
MITAP document. As subjects could give multiple answers, we assessed answers as either
being exactly the same as the gold standard, or containing at least the gold standard (Fig. 2).
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Figure 2 Summary of the results of the ‘‘20 Questions’’ Experiment. The answers of the test subjects
were divided over four quadrants: 0–25%, 25–50%, 50–75% and 75–100%, where e.g., 0–25% means that
the number of questions that were only answered correctly by 0-25% of the test subjects and 75–100%
meaning that these questions were answered correctly by 75–100% of the participants. A total of 44 ques-
tions were presented to test subjects. In blue, we show only answers with exactly the Gold Standard as cor-
rect.
Broadly, the results showed a very high-level of test subject agreement, averaging at
around 73% for Gold Standard only and 84% for at least Gold Standard. Terms that
were put in the right category by all test subjects included ‘immunomagnetic separation’
(Section 1. Cell separation process) and ‘Spanish regulatory agency (AEMPS)’ (Section 4.
Regulatory Authority). Terms that test subjects were struggling with (0–50% agreement)
included ‘‘cytomegalovirus (CMV)’’ for which the Gold Standard was antigen (see Section
2. Differentiation and Induction of Tolerogenicity), but that could also correctly be put
under ‘characteristics of the organism’ (Section 1). Another example of a term often placed
under the wrong subheading was: ‘‘mice were obtained from the Jackson Laboratory,’’
which was often placed under ‘species and strain’ (Section 1), but for which the Gold
Standard was ‘characteristics of the organism’ (Section 1). For these terms, where the
document was shown to lack in clarity, we adjusted the MITAP document accordingly;
for example, we now state explicitly under ‘characteristics of the organism’ that authors
should indicate the source of purchase.
PREVALENCE OF MITAP DATA IN EXTANT PAPERS
The purpose of the MITAP document is to ensure that authors provide sufficient basic
information about their tolAPC production protocol. An implicit assumption is that
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Figure 3 Agreement of published tolDC papers with theMITAP document.Graph showing the results
of a total of twenty tolAPC papers. Green square: category included in the publication; Yellow triangle:
category included in the publication, but some details missing; Red circle: category not included in the
publication; -gap- information not present because not relevant for the publication.
currently some or all of this information is not being routinely described. To test this
assumption, we reviewed a number of papers about tolAPC, and for each, we determined
whether the data required by the MITAP document was present or not.
In detail, forty-two tolAPC papers were selected (predominantly from members of
AFACTT or from researchers wellknown in the field), randomized and the first twenty
were read in detail. For each section of MITAP, we determined whether the information
required was either: directly stated in the paper or reference (Fig. 3: green squares), whether
it was possible to infer from other information given in the paper (Fig. 3: yellow triangles),
whether all details were present or only partly (Fig. 3: yellow triangles) or whether the
information was not present at all (Fig. 3: red circles). For example, Section 1-ai of MITAP
describes the species of the experimental organism. A paper with the phrase ‘‘human’’ or
‘‘Homo sapiens’’ would fall into the first category (included in the publication) one referring
to ‘‘patients’’ would fall into the second category (included but some details missing ). Many
papers do not describe their experimental methodology, but instead refer to another paper
(‘‘as described previously’’); in this case, we checked the paper up to two references away
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and if found the information was considered as ‘present’ (Fig. 3: green squares), if not it
was considered as ‘not present’ (Fig. 3: red circles). This work was performed by one of us
(RS) who is a post-doctoral scientist with 6 years experience in the discipline.
Results are shown in Fig. 3. This shows that no papers have all the information required
by MITAP, and that most have substantial gaps. We can also see that while there is a
relatively high degree of conformity between different papers: e.g., species and growth
media are commonly reported; cell number, viability and culture container are rarely
documented.
SUSTAINABILITY
One significant issue with resources such as MITAP is their sustainability. Previous
research has shown that uniform resource identifiers (URIs; i.e., URLs or Web addresses)
given in papers have short half-lives (around a 25% loss three years after publication
(Wren, 2008)), and either move or become inaccessible, in many cases before the papers
have been published. This can happen either because the web hosting is not stable, or
fails, or because the domain providing the URI is not maintained. To alleviate these
difficulties with MITAP, neither the URIs nor the hosting of the documents require
active maintenance by the authors of this paper. We have used a permanent identifier
(http://w3id.org/ontolink/mitap) thereby providing a re-direction step. The primary
hosting of the resource is provided by Internet Archive (http://archive.org). Both of these
organisations have sustainability as their key aim. Maintenance of MITAP documents
as live, web-resources therefore requires no active contribution from the authors of this
paper. Either archive.org or w3id.org need to fail before MITAP cannot be maintained at
the stated location.
We have also given explicit consideration to data formats for our documents. Resources
are available as Word docs and PDFs, providing typographical elegance and familiarity
to the community, but also an extremely simple HTML representation, ensuring vendor-
neutrality and future-proofing of the knowledge contained within them.
DISCUSSION
The tolAPC community has advanced significantly in the last 15 years, from the initial
discoveries of how to culture APC with potent immune-regulatory properties, through to
clinical trials. At the current time, however, most investigators are operating as a ‘‘cottage
industry’’: individual labs working with different cell isolation techniques, procedures to
induce stable tolerogenic properties in the cells, and investigating different therapeutic
outcomes. Against this heterogeneous background, it becomes difficult to compare
investigations between different laboratories, raising concerns about reproducibility
(Ioannidis, 2005; Boulton, 2016).
The MITAP document that we have described here will, of course, not address all of
these issues, however as a minimum guidelines tool for reporting of protocols, it should at
least address the issue of data heterogeneity; different laboratories may still use different
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protocols to generate tolAPC, but at least we will be clear about this diversity, and have a
greater understanding of what these differences are.
We have been careful in the process of building MITAP not to produce a document that
is overly complex. Unlike many other minimum information documents, we have actively
tested it with independent, essentially untrained annotators (test subjects). We have shown
that it is possible, under these circumstances, to provide the information required in a clear
and consistent manner. We believe that it should be possible for authors to complete the
MITAP document in approximately 30 min. We also believe that this process should not be
a burden to researchers; in our experience, we have adopted use of the MITAP document
in writing our own papers, and believe that having a clear checklist to follow simplifies
rather than confuses.
The process of building the MITAP document has been a highly collaborative one
which has been a useful exercise in and of its own right: the degree of heterogeneity in the
community has come as a surprise to many of those involved in this work. By analyzing
extant papers, we have also shown that there is a discrepancy between the information
that the community considers important and wants to receive about a tolAPC production
protocol and the information that they actually report. For example, very few papers
describe the viability of tolAPC at the end of the production process, although we consider
it extremely likely that most researchers do actually measure this. Moreover, we can see no
a priori reason why culture media largely is reported while culture container largely is not.
We believe that wide adoption could also contribute toward greater consideration of
data management in the tolerogenic cell therapies community in general. For example,
the MIATA project was recently extended to include NK cells (called MIANKA), and
a similar approach could be taken by MITAP to include other regulatory cells, such as
myeloid-derived suppressor cells, mesenchymal stem cells, and even T regulatory cells.
Furthermore, unlike many minimum information efforts, we have considered upfront
long-term sustainability of the documents and the URIs used to refer to them. Our
sustainability plan is robust and does not require active involvement of any of the authors.
Of course, there is much work remaining. The production of tolAPC is only a small part
of the overall process. Moreover, we are only attempting to standardize the reporting of
protocols, and not the standardisation of the protocols themselves. Finally, we currently
have no common location or database which can store the experimental data, such as exists
for instance with microarray or genomic data. MITAP is a first step, laying the groundwork
for further collaboration.
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